Details

Autor(en) / Beteiligte

• Smaili, F
• Boudjella, A
• Dib, A
• Braikia, S
• Zidane, H
• Reggad, R
• Bendib, A
• Abdelouahab, A
• Bereksi-Reguig, F
• Yekrou, D
• Bentouati, A
• Filali, T
• Chirouf, A
• Djehal, N
• Mahfouf, H
• Mechiat, F
• Tadjerouni, H
• Sedkaoui, C
• Hikem, M
• Amber, A
• Bouzid, K
• Ladjeroud, A
• Ghomari, S
• Aris, H
• Saidi, S
• Larhbali, R
• Saidi, MA
• Haddouche, A
• Kedar, M
• Bounedjar, A
• Talha, S
• Benbrahim, W
• Ammari, A
• Boushaba, A
• Rabah, A
• Ameziane, N
• Benabdallah, F
• Djedi, H
• Kouadri, N
• Bensalem, A
• Djeghim, S
• Oukkal, M
• Hadjam, F
• Larbaoui, B
• Rekai, K
• Azzouz, N
• Badaoui, A
• Abid, M
• Abada, M
• Moussei, A
• Benmehidi, F
• Benzidane, N
• Boualga, K
• Mesli, S

Titel

Epidemiology of breast cancer in women based on diagnosis data from oncologists and senologists in Algeria

Ist Teil von

• Cancer treatment and research communications, 2020, Vol.25, p.100220-100220, Article 100220

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Mortality rate due to breast cancer reached 3.23% at 12 months in Algeria.•22 new cases per 100,000 inhabitants were identified over 8 months.•Late diagnosis is one of the risks compromising the prognosis of women with a diagnosis of breast cancer where preventive screening measures must be optimised. Breast cancer (BC) is a major health issue threatening women's life. No reliable epidemiological data on BC diagnosed by oncologists/senologists are available in Algeria. The BreCaReAl study, a non-interventional prospective cohort study, included adult women with confirmed BC in Algeria. Disease incidence, patients and disease characteristics, treatment patterns, and mortality rate were recorded up to 12 months of follow-up. Overall, 1,437 patients were analysed: median age was 48 [41;57] years and 337 (23.5%) women had a family history of BC. BC incidence was 22.3 (95% CI: 21.5; 23.2) cases per 100,000 inhabitants over 8 months. Delayed diagnosis was reported in 400 (29.2%) patients. First line of treatments were mainly chemotherapy and surgery. Twenty-eight serious adverse events were reported including 10 (37.0%) events which led to death. Mortality rate reached 3.2% at 12 months A delayed diagnosis highlights the importance of implementing more effective screening strategies.